A heat-stable cytotoxic factor produced by Achromobacter xylosoxidans isolated from Brazilian patients with CF is associated with in vitro increased proinflammatory cytokines

Journal of Cystic Fibrosis

Volumn 11, Issue 4, 2012, Pages 305-311

  Mantovani, Rebeca P ^a   Levy, Carlos E ^a   Yano, Tomomasa ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

A. xylosoxidans; Cystic fibrosis; Cytotoxin; Endotoxin; Lung inflammation

Indexed keywords

CYTOTOXIC FACTOR; ENDOTOXIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; POLYMYXIN B;

ACHROMOBACTER XYLOSOXIDANS; ARTICLE; BRAZIL; CELL CONTACT; CELL DEATH; CELL GROWTH; CELL JUNCTION; CELL LOSS; CELL STRUCTURE; CELL VACUOLE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAT; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; MITOCHONDRION;

ACHROMOBACTER DENITRIFICANS; BRAZIL; CARCINOMA, MUCOEPIDERMOID; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; CYSTIC FIBROSIS; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; PNEUMONIA; SPUTUM; VIRULENCE;

EID: 84862498757     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.02.002     Document Type: Article

References (26)

1. Payseur B.A., Nachman M.W. Microsatellite variation and recombination rate in the human genome. Genetics 2000, 196:1285-1298.
2. Lyczak J.B., Cannon C.L., Pier G.B. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15:194-222.
3. Bye M., Ewig J.M., Quittell L.M. Cystic fibrosis. Lung 1994, 172:251-270.
4. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
5. Hansen C., Pressler T., Høiby N., Gormsen M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 2006, 5:245-251.
6. Burns J.L., Emerson J., Stapp J.R., Yim D.L., Krzewinski J., Louden L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27(1):158-163.
7. Caraher E., Reynolds G., Murphy P., McClean S., Callaghan M. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro. Eur J Clin Microbiol Infect Dis 2007, 26:213-216.
8. Caraher E., Collins J., Herbert G., Murphy P.G., Gallagher C.G., Crowe M.J., et al. Evaluation of in vitro virulence characteristics of the genus Pandoraea in lung epithelial cells. J Med Microbiol 2008, 57:15-20.
9. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.Ø., Bjarnsholt T., Høiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros 2010, 9:51-58.
10. Chmiel J.F., Berger M., Konstan M.W. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002, 23:5-27.
11. Yabuuchi E., Ohyama A. Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol 1971, 15:477-481.
12. Konstan M.W., Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997, 24:137-142.
13. Hutchison M.L., Bonell E.C., Poxton I.R., Govan J.R. Endotoxic activity of lipopolysaccharides isolated from emergent potential cystic fibrosis pathogens. FEMS Immunol Med Microbiol 2000, 27:73-77.
14. Cooperstock M.S. Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother 1974 Oct, 6:422-425.
15. Palfreyman R.W., Watson M.L., Eden C., Smith A.W. Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products. Infect Immun 1997, 65:617-622.
16. Tan K., Conway S.P., Brownlee K.G., Etherington C., Peckham D.G. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002, 34:101-104.
17. Steinkamp G., Wiedemann B., Rietschel E., Krahl A., Gielen J., Bärmeier H., et al. Prospective evaluation of emerging bacteria in cystic fibrosis. J Cyst Fibros 2005, 4:41-48.
18. Cystic Fibrosis Foundation Patient Registry. Annual Report. Bethesda, Maryland, 1995, 1996, 1997, 1999, 2002.
19. Mello M.L., Vidal B. Práticas em biologia celular 1980, 71. Edgard Blucher, Rio de Janeiro.
20. Kim J.Y., Sajjan U.S., Krasan J.P., LiPuma J.J. Disruption of tight junctions during traversal of the respiratory epithelium by Burkholderia cenocepacia. Infect Immun 2005, 73:7107-7112.
21. Romano L., Bellodi S., Lugani F., Manno G. Alcaligenes as a pathogen in airways chronic infection in cystic fibrosis. Pediatr Pulmonol 2003, 35:412-413.
22. Massion P.P., Inoue H., Richman-Eisenstat J., Grunberger D., Jorens P.G., Housset B., et al. Novel Pseudomonas product stimulates interleukin-8 production in airway epithelial cells in vitro. J Clin Invest 1994, 93:26-32.
23. Bonfield T.L., Panuska J.R., Konstan M.W., Hilliard K.A., Hilliard J.B., Ghnaim H., et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995, 152:2111-2118.
24. Duggan J.M., Goldstein S.J., Chenoweth C.E., Kauffman C.A., Bradley S.F. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis 1996, 23:569-576.
25. McIntire F.C., Barlow G., Siev ert H., Finley R., Yoo A. Studies on a lipopolysaccharide from Escherichia coli. Heterogeneity and mechanism of reversible inactivation by sodium deoxycholate. Biochemistry 1969, 8:4063-4067.
26. Ribi E., Anacker R.L., Brown R., Haskins W.T., Malmgren B., Milner K.C., et al. Reaction of endotoxin and surfactants I. Physical and biological properties of endotoxin treated with sodium deoxycholate. J Bacteriol 1966, 92:1493-1509.